1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Rituximab for the first-line treatment of stage III-IV follicular lymphoma

Technology appraisal guidance [TA243] Published date: 25 January 2012

  • Guidance
  • Tools and resources
  • Information for the public
  • History
  • Overview
  • 1 Guidance
  • 2 Clinical need and practice
  • 3 The technology
  • 4 Evidence and interpretation
  • 5 Implementation
  • 6 Related NICE guidance
  • 7 Review of guidance
  • Appendix A: Appraisal Committee members and NICE project team
  • Appendix B: Sources of evidence considered by the Committee
  • Changes after publication
  • About this guidance
  • Share
    • Share
    • Linked In
    • Twitter
    • Facebook
    • Email
    • More...
  • Download

Guidance

  • Next

Changes after publication

Changes after publication

February 2014: implementation section updated to clarify that rituximab is recommended as an option for treating stage III-IV follicular lymphoma.

July 2012: minor maintenance

June 2012: minor maintenance

  • National Institute for Health and Care Excellence (NICE)

  • Next
NICE
  • About NICE
  • Into practice
  • News
  • Contact us
  • Leave feedback
  • Jobs
  • Newsletters and alerts
  • Blog
  • Twitter
  • YouTube
  •   Facebook
  • LinkedIn

Explore

  • Guidance
  • Pathways
  • Standards and indicators
  • Evidence search
  • BNF
  • BNFC
  • Clinical knowledge summaries
  • Journals and databases

Reusing our content

  • Reuse information
  • NICE UK Open Content Licence

Guidance app

  • Android
  • iOS

Get involved

  • Register as a stakeholder
  • Citizens council
  • Consultations
  • Fellows and scholars
  • Join a committee
  • Meetings in public
  • Student champions
  • Tenders
  • Public involvement
  • Accessibility
  • Freedom of information
  • Syndication services
  • Glossary
  • Terms and conditions
  • Privacy notice

© NICE [year]. All rights reserved. Subject to Notice of rights.